Epidermal growth factor receptor as a biomarker for cervical cancer (Q37843137)

24 August 2017

1 reference

title

Epidermal growth factor receptor as a biomarker for cervical cancer (English)

1 reference

24 August 2017

0 references

cervix uterine cancer

1 reference

H Arias-Pulido

2

0 references

author name string

T Soonthornthum

1

1 reference

24 August 2017

N Joste

3

1 reference

24 August 2017

L Lomo

4

1 reference

24 August 2017

C Muller

5

1 reference

24 August 2017

T Rutledge

6

1 reference

24 August 2017

C Verschraegen

7

1 reference

24 August 2017

publication date

16 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

22

1 reference

24 August 2017

issue

10

1 reference

24 August 2017

page(s)

2166-2178

1 reference

Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Novel chemotherapy approaches for cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Why the epidermal growth factor receptor? The rationale for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

The causal relation between human papillomavirus and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

The biochemical and biological functions of human papillomavirus type 16 E5 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Transcriptional regulation of the EGF receptor promoter by HPV16 and retinoic acid in human ectocervical epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Absence of epidermal growth factor receptor mutations in cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Epidermal growth factor receptor-targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Prognostic value of epidermal growth factor receptor expression in cervical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Epidermal growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Optical imaging of cervical pre-cancers with structured illumination: an integrated approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Fluorescent nanocrystals for use in early cervical cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Cyclooxygenases: structural, cellular, and molecular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Analysis of chromosomes 3, 7, X and the EGFR gene in uterine cervical cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Correlation between EGFR and c-erbB-2 oncoprotein status and response to neoadjuvant chemotherapy in cervical carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Epidermal-growth-factor receptor correlates negatively with cell density in cervical squamous epithelium and is down-regulated in cancers of the human uterus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Epidermal growth factor 61 A/G polymorphism and uterine cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Overexpression of c-kit protein is an infrequent event in small cell carcinomas of the uterine cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

Cyclooxygenase-2 and Epidermal Growth Factor Receptor Expressions in Different Histological Subtypes of Cervical Carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ723

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ723

1 reference

24 August 2017

1 reference